AML – acute myeloid leukemia, immune therapeutics, checkpoint inhibition therapy, RNAseq analysis, functional genomic data, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

IntroductionThe implementation of small-molecule and immunotherapies in acute myeloid leukemia (AML) has been challenging due to genetic and epigenetic variability amongst patients. There are many potential mechanisms by which immune cells could influence small-molecule or immunotherapy responses, yet, this area remains understudied.MethodsHere we performed cell type enrichment analysis from over 560 AML patient bone marrow and peripheral blood samples from the Beat AML dataset to describe the functional immune landscape of AML.ResultsWe identify multiple cell types that significantly correlate with AML clinical and genetic features, and we also observe significant correlations of immune cell proportions with ex vivo small-molecule and immunotherapy responses. Additionally, we generated a signature of terminally exhausted T cells (Tex) and identified AML with high monocytic proportions as strongly correlating with increased proportions of these immunosuppressive T cells.DiscussionOur work, which is accessible through a new “Cell Type” module in our visualization platform (Vizome; View item/), can be leveraged to investigate potential contributions of different immune cells on many facets of the biology of AML.